HOME >> BIOLOGY >> NEWS
Search for cholesterol absorption genes narrows to two chromosome regions

Two people eat the same egg, cheese and ham muffin for breakfast, yet one absorbs significantly more cholesterol into his or her blood than the other. Why?

The answer, and all of its implications for combating heart disease, remains stubbornly hidden within our DNA. In recent genetic studies with lab mice, however, researchers at The Rockefeller University have begun to close in on the culprit genes.

"By determining the genetic basis behind the observation that some people absorb 25 percent of cholesterol from their diet, while others absorb up to 75 percent, we hope to develop new treatments to protect this latter group," says senior co-author Jan. L. Breslow, M.D., head of The Rockefeller University's Laboratory of Biochemical Genetics and Metabolism and former national president of the American Heart Association.

The researchers hope that the identification of genes that regulate cholesterol absorption in mice will lead them to the location of similar genes in humans - and ultimately to the development of drugs that specifically reduce cholesterol absorption and protect against coronary heart disease, the number one cause of death in the United States.

In the Dec. 10 issue of the Proceedings of the National Academy of Sciences (published online Nov. 22), the Rockefeller scientists report the use of mouse "genetic linkage mapping" technology to narrow the location of genes responsible for regulating the absorption of plant fatty molecules called "plant sterols" - markers of cholesterol absorption - to two distinct regions on chromosome 2 and 14.

While the exact location of the genes has not been deduced, the results indicate that the researchers have indeed uncovered their general vicinity: one of the putative sites has an incredibly high probability - a billion to one - of carrying the suspected genes.

"We are excited because our data analysis shows that cholesterol absorption genes are very likely hiding in chr
'"/>

Contact: Whitney Clavin
clavinw@rockefeller.edu
212-327-7900
Rockefeller University
5-Dec-2002


Page: 1 2 3 4

Related biology news :

1. Search and destroy protein turns tables on HIV
2. Search for macular degeneration genes narrows
3. Search beneath lawns provides insight into backyard biodiversity
4. Searching for the real waterworld
5. Search for schizophrenia genes takes an unplanned turn
6. Searching for a genetic needle in a genome haystack
7. Searching for the secrets of drug-free transplants
8. Searching for new medications to treat alcoholism
9. Searching for biochemical markers in children of alcoholics
10. Search and support for the rare white abalone is on; sex must occur with close neighbors
11. Investigators Identify Suspect In Search For Stress-Sniffles Link

Post Your Comments:
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: